Menu Search
Equities

Adtalem Global Education Inc

DVY:FRA

Adtalem Global Education Inc

Actions
  • Price (EUR)82.50
  • Today's Change-0.50 / -0.60%
  • Shares traded30.00
  • 1 Year change+63.37%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 07:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Adtalem Global Education Inc. is a provider of healthcare education in the United States, preparing a diverse workforce with academic programs. Its healthcare programs include nursing, medicine, veterinary medicine, social and behavioral sciences and more. Its segments include Chamberlain, Walden, and Medical and Veterinary. Chamberlain segment offers degree and certificate programs in the nursing and health professions postsecondary education industry. Walden segment offers degree and certificate programs, including those in nursing, education, counseling, business, psychology, public health, social work and human services, public administration and public policy, and criminal justice. Medical and Veterinary segment offers degree and certificate programs in the medical and veterinary postsecondary education industry. This segment includes American University of the Caribbean School of Medicine, Ross University School of Medicine, and Ross University School of Veterinary Medicine.

  • Revenue in USD (TTM)1.63bn
  • Net income in USD172.00m
  • Incorporated1987
  • Employees4.62k
  • Location
    Adtalem Global Education Inc500 W Monroe St Fl 28CHICAGO 60661-3773United StatesUSA
  • Phone+1 (630) 515-7700
  • Fax+1 (302) 636-5454
  • Websitehttps://www.adtalem.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.